Segment Information

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Information

(11)        Segment Information

The Company has four reportable segments which include: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products. The Company had five reportable segments in 2021 which also included Radiological Services. The Radiological Services business segment included field services, gemstone processing, and source disposal. As the Company is no longer engaged in field services and gemstone processing, which made up the substantial portion of activities of this segment, separate reporting of this segment has been discontinued. The Company continues to engage in source disposal activities and has begun reporting these activities under the Nuclear Medicine Standards segment beginning January 1, 2022.

Information regarding the operations and assets of these reportable business segments is contained in the following table:

	Three months ended June 30,				Six months ended June 30,
Sale of Product	2022		2021		2022		2021
Radiochemical Products	$	1,380,039	$	1,228,209	$	3,005,962	$	1,889,386
Cobalt Products		99,146		576,994		271,052		695,367
Nuclear Medicine Standards		955,623		954,693		1,965,235		2,145,642
Fluorine Products		—		—		—		22,013
Total Segments		2,434,808		2,759,896		5,242,249		4,752,408
Corporate revenue		—		—		—		—
Total Consolidated	$	2,434,808	$	2,759,896	$	5,242,249	$	4,752,408

	Three months ended June 30,				Six months ended June 30,
Depreciation and Amortization	2022		2021		2022		2021
Radiochemical Products	$	7,415	$	78,430	$	49,345	$	157,977
Cobalt Products		12,140		12,399		24,281		26,038
Nuclear Medicine Standards		28,587		18,120		57,233		34,742
Fluorine Products		26,095		31,158		52,190		57,253
Total Segments		74,237		140,107		183,049		276,010
Corporate depreciation and amortization		10,196		6,941		20,502		11,240
Total Consolidated	$	84,433	$	147,048	$	203,551	$	287,250

	Three months ended June 30,						Six months ended June 30,
Segment Income (Loss)	2022			2021			2022			2021
Radiochemical Products	$	505,630		$	404,457		$	2,976,293		$	408,882
Cobalt Products		(42,332	)		208,581			(55,407	)		178,484
Nuclear Medicine Standards		(26,144	)		110,085			11,572			373,403
Fluorine Products		(42,343	)		(31,627	)		(74,173	)		(65,141	)
Total Segments		394,811			691,496			2,858,285			895,628
Corporate loss		(666,859	)		(872,883	)		(1,875,288	)		(1,678,167	)
Net Income	$	(272,048	)	$	(181,387	)	$	982,997		$	(782,539	)

	Three months ended June 30,				Six months ended June 30,
Expenditures for Segment Assets	2022		2021		2022		2021
Radiochemical Products	$	—	$	—	$	—	$	3,103
Cobalt Products		—		—		—		16,592
Nuclear Medicine Standards		—		32,911		51,100		167,911
Fluorine Products		4,100		—		4,100		4,060
Total Segments		4,100		32,911		55,200		191,666
Corporate purchases		—		—		—		—
Total Consolidated	$	4,100	$	32,911	$	55,200	$	191,666

	June 30,		December 31,
Segment Assets	2022		2021
Radiochemical Products	$	924,131	$	2,890,590
Cobalt Products		563,906		597,420
Nuclear Medicine Standards		1,358,491		2,259,759
Fluorine Products		5,205,266		5,258,823
Total Segments		8,051,794		11,006,592
Corporate assets		8,500,270		5,320,550
Total Consolidated	$	16,552,064	$	16,327,142